Design, synthesis, in vitro and in vivo evaluation of novel pyrrolizine-based compounds with potential activity as cholinesterase inhibitors and anti-Alzheimer's agents

El-Sayed N. A., Farag A. E., Ezzat M. A. F., Akincioglu H., GÜLÇİN İ., Abou-Seri S. M.

BIOORGANIC CHEMISTRY, cilt.93, 2019 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 93
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1016/j.bioorg.2019.103312
  • Dergi Adı: BIOORGANIC CHEMISTRY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Anahtar Kelimeler: Alzheimer's disease, Pyrrolizine derivative, Acetylcholinesterase inhibitor, Butyrylcholinesterase inhibitor, Amyloid beta aggregation inhibition, In vivo study, ACETYLCHOLINESTERASE, DISEASE, MEMORY, DERIVATIVES
  • Atatürk Üniversitesi Adresli: Evet

Özet

Novel series of pyrrolizine based compounds (4-6 and 9-11) were designed, synthesized and evaluated as potential anti-Alzheimer agents. Most of the tested compounds showed selectivity to hAChE over hBChE and effectively inhibited self-induced amyloid beta aggregation in vitro. Among these derivatives, compound 10 displayed high selectivity towards hAChE (Ki= 1.47 +/- 0.63 mu M for hAChE and Ki= 40.15 +/- 3.31 mu M for hBChE). However, compound 11 displayed dual inhibitory effect against hAChE and hBChE at submicromolar range (Ki= 0.40 +/- 0.03 and 0.129 +/- 0.009 mu M, respectively). Kinetic studies of the new ligands showed competitive type inhibition for both hAChE and hBChE. Moreover, compounds 10 and 11 showed lower or comparable cytotoxicity to donepezil against human neuroblastoma (SH-SY5Y) and normal human hepatic (THLE2) cell lines. In vivo studies confirmed that both compounds were able to improve cognitive dysfunction of scopolamine-induced AD mice. Finally, molecular docking simulation of compounds 10 and 11 in hAChE active site showed good agreement with the obtained pharmaco-biological results.